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ABSTRACT 
Purpose:  Kilovoltage intrafraction monitoring (KIM) is a real-time image guidance method that uses 
widely available radiotherapy technology, i.e. a gantry-mounted x-ray imager. We report on the 
geometric and dosimetric results of the first patient treatment using kilovoltage intrafraction 20 
monitoring (KIM) which occurred on September 16, 2014.   
 
Methods:  KIM uses current and prior 2D x-ray images to estimate the 3D target position during 
cancer radiotherapy treatment delivery.  KIM software was written to process kilovoltage (kV) images 
streamed from a standard C-arm linear accelerator with a gantry mounted kV x-ray imaging system.  25 
A 1200 pre-treatment kV imaging arc was acquired to build the patient-specific 2D to 3D motion 
correlation. The kV imager was activated during the megavoltage (MV) treatment, a dual arc VMAT 
prostate treatment, to estimate the 3D prostate position in real-time. All necessary ethics, legal and 
regulatory requirements were met for this clinical study.  The QA processes were completed and peer 
reviewed. 30 
 
Results:  During treatment, a prostate position offset of nearly 3 mm in the posterior direction was 
observed with KIM.  This position offset did not trigger a gating event. After the treatment, the 
prostate motion was independently measured using kV/MV triangulation, resulting in a mean 
difference of less than 0.6 mm and standard deviation of less than 0.6 mm in each direction.  The 35 
accuracy of the marker segmentation was visually assessed during and after treatment and found to be 
performing well.  During treatment there were no interruptions due to performance of the KIM 
software.  
 
Conclusions:  For the first time, KIM has been used for real-time image guidance during cancer 40 
radiotherapy. The measured accuracy and precision were both sub-millimeter for the first treatment 
fraction. This clinical translational research milestone paves the way for the broad implementation of 
real-time image guidance to facilitate the detection and correction of geometric and dosimetric errors, 
and resultant improved clinical outcomes, in cancer radiotherapy. 
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INTRODUCTION 
Tumors in the thorax, abdomen and pelvis move during cancer radiotherapy. Many methods have 
been developed to measure the position of the tumor in real-time including kilovoltage, megavoltage, 
and kilovoltage/megavoltage/respiratory sensor combinations, magnetic resonance imaging, and 50 
ultrasound. Three implanted marker-based methods that have been applied clinically are stereoscopic 
kilovoltage x-ray,1-3 electromagnetic4 and radioisotope tracking.5 These methods all rely on hardware 
that is additional to a modern linear accelerator. In this work, we describe the first clinical 
implementation of kilovoltage intrafraction monitoring (KIM), a method that uses a gantry-mounted 
kilovoltage x-ray imager to determine the real-time 3D position of implanted markers during cancer 55 
radiotherapy.  
 
METHODS 
The KIM method, hardware, software and clinical process are briefly described. All necessary ethics, 
legal and regulatory requirements were met.  The legal processes included agreements between the 60 
clinical site, the Royal North Shore Hospital and the additional parties providing software or 
hardware, including the University of Sydney, Aarhus University and Varian Medical Systems.  The 
regulatory pathway included filing a Clinical Trial Notification with the Australian Therapeutic 
Goods Administration.   
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KIM method 
The heart of the KIM method is the 2D to 3D transformation first described by Poulsen in 20086 and 
extended in 2009.7 This transformation relies on the correlation of motion between the observed and 
unobserved directions. The motion in the unobserved direction is estimated based on the correlation of 
motion computed using prior observations from angles where the currently unobserved direction was 70 
observed. A probability density function (pdf) of the correlations is determined via maximum 
likelihood. The pdf, recomputed after each new image, is used to estimate the position of the markers 
in the unobserved direction, yielding the 3D target position.   
Another key element of KIM is the robust automated marker detection algorithm8 where the 
marker shape is known a priori and the pose of each marker is determined during a short pre-75 
treatment arc.  
 
KIM hardware 
KIM requires a gantry mounted x-ray imager in which the images can be acquired during treatment 
and the images and gantry angles can be immediately accessed. In principal, this requirement covers 80 
linear accelerators from Elekta, Varian and other manufacturers. The current implementation used a 
Varian (Palo Alto, CA) Trilogy linear accelerator with an On Board Imager. The images were 
streamed via a frame grabber cable to the iTools Capture software (Varian) on a stand-alone research 
computer on which the KIM software was also installed. Though relatively minor, this additional 
hardware would not be necessary in a vendor implementation of KIM as the images are directly 85 
streamed to the treatment console. In our set-up, there was no connection between the KIM software 
and the treatment console, and therefore additional safety checks were necessary, and the beam pause 
and couch correction when motion exceeding the gating threshold was observed is manually 
performed.   
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KIM software 
The KIM software is an in-house written a C# application running in the .net environment.  The 
interface was developed with substantial radiation therapist input to maximize key information 
display and screen space. Examples of the interface are shown in Figure 1.  The clinically-used 
version of the KIM software was branched from the ongoing research version, with changes, bug 95 
tracking and feature requests under version control. Algorithm parameters include the number of 
images used to build the pdf (when more than 500 images are acquired, the oldest images are 
discarded), three-image frame averaging and the automatic switch to a joint template if the markers 
overlap.9  The latency of the KIM hardware/software was measured to be less than 350 ms.10   
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Figure 1.  The KIM user interface. Key features include Top Left: the real-time prostate image 
showing the detected marker positions in the image (red crosses) and also the marker positions from 
the treatment plan in the same projection image (green squares); Middle: the therapist action directive 
(continue, warning, stop treatment); Top Right: the patient picture and medical record number for 105 
patient safety purposes and Bottom: the measured motion trace in each dimension.   
 
Clinical process 
The patient was treated as per the clinical trial protocol (NCT017424030). During treatment planning, 
to avoid manual entry of offsets at treatment delivery, the treatment isocenter is set to the center of the 110 
three markers. Through an Eclipse script, the individual marker positions, patient name and medical 
record number (MRN) are written to a file. This file along with the patient picture is put into a folder 
on the KIM treatment computer.  Prior to treatment, the file and patient picture are read into the KIM 
software. For safety, the patient name, MRN and picture are compared to that on the treatment 
console as currently there is no communication between the KIM computer and the treatment console. 115 
The marker positions are used to define the initial search region for the marker detection software, and 
used throughout treatment for safety as the detected marker positions and the marker arrangement 
should be close to that from the original CT scan.  The current couch position is manually entered to 
guide fast correction in the case of a gating event.  
Prior to treatment, a 120-degree pre-treatment kV arc is acquired to build the KIM pdf. After 120 
a 3-4 second delay, treatment is initiated with continuous kV imaging during which the images are 
processed and the 3D prostate position is determined. KIM during treatment is a real-time 
implementation of a previously published offline KIM clinical study,11 with Figure 3 of that paper 
showing the workflow.  The clinical protocol gating parameters for the study requires the treatment to 
be paused if the target moves 3 mm or more from the planned position for 5 seconds or more. In the 125 
current implementation of KIM, the beam pause or gating event is manually performed by the 
radiation therapist. 
The kV image acquisition was the same as a previous offline KIM prostate study.11 Briefly, 
the images were acquired at 10 Hz with exposure parameters 125 kVp, 80 mA and 13 ms. The field 
size was 6×6cm2. To reduce the effects of the MV scatter on the kV images the source-detector 130 
distance was 180 cm.  With these parameters over a 39-fraction treatment the physical dose is 
estimated to be 1.2 Gy,12 with an effective dose of 50 mSv.13 The increased imaging dose is a 
disadvantage of KIM, however there are a number of strategies to substantially reduce the imaging 
dose, several are which are described in Ng et al.11   
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Patient treatment details 
The patient for the trial had localized stage T2a prostate cancer with PSA 7 nG/mL and a Gleason 
score of 7. He is being treated to 80 Gy in 40 fractions using dual arc RapidArc and has three 140 
implanted gold markers of diameter 1.2 mm and length 3 mm. To account for contouring variability 
and other uncertainties in the radiotherapy process, his CTV to PTV margins were 7 mm in all 
directions except posteriorly where the margin was 5 mm. The first patient to be treated with KIM is 
shown in Error! Reference source not found..   
 145 
 
Figure 2.  The first KIM patient in treatment position.  
 
KIM quality assurance 
The quality assurance (QA) process was adapted for KIM target position monitoring from that used 150 
for real-time electromagnetic monitoring by Santanam et al.14 The KIM QA process is described in 
more detail in Ng et al.10  
 
RESULTS AND DISCUSSION 
The total treatment time for the fraction, from walking into the bunker to exiting the bunker, was 26 155 
minutes. This time included CBCT imaging and all of the typical first fraction checks. As the KIM 
software is not integrated with the other treatment software, there are some process inefficiencies and 
additional checks implemented which increase the total treatment time.   
 
The pre-treatment arc, and two treatments were completed with the kV images being streamed to the 160 
KIM software and processed as shown in Figure 1. During treatment, a prostate position offset of 
nearly 3 mm in the posterior direction was observed with KIM, however this positional offset did not 
exceed the 3 mm for 5 seconds action threshold.  An anonymized movie of the treatment is attached 
as supplemental material.  To quantify the accuracy of the KIM method, kV/MV triangulation11, 13 was 
performed where the markers were within the treatment field and clearly apparent on an MV image 165 
the cine acquisition.   Fiducial marker positions measured retrospectively by kV/MV triangulation and 
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the corresponding fiducial marker positions estimated in real-time by KIM are shown in Figure 3, 
along with the direct position measurements determined from kV/MV triangulation.11, 15 Averaged 
over all of the markers and images where the markers were clearly apparent the mean difference 
between the retrospective triangulation and real-time KIM were, in mm, LR 0.22, SI 0.56 and AP -170 
0.07. The standard deviation of the difference was, in mm, LR 0.57, SI 0.27 and AP 0.32. 
 
 
Figure 3.  Fiducial marker positions measured retrospectively by kV/MV triangulation (triangles) and 
the corresponding fiducial marker positions estimated in real-time by KIM (squares).  175 
 
From the measured motion, dose reconstruction was performed using the method of Poulsen.16 The 
planned and delivered isodose distributions and dose volume histogram curves are shown in Figure 4 
and Figure 5 respectively.  It should be noted that the current clinical version of KIM, and the dose 
reconstruction method, do not measure or account for rotation or deformation that will have an impact 180 
on the actual dose delivered to the patient. Even though the gating threshold was not exceeded for this 
fraction, there was benefit to KIM in the ability to estimate the delivered dose, including motion, 
which is not possible without KIM on a standard linac.  Furthermore, had KIM been integrated with 
MLC or couch adaptation, which we plan to do in the future, an improvement in the agreement 
between the planned and delivered doses would have been possible.17  185 
 
 
Figure 4.  (a) Planned isodose distributions and (b) estimated delivered isodose distributions based on 
the KIM-measured motion trace for fraction 1 of patient 1.  Dose levels >80% are shown. Contoured 
are the bladder (blue), PTV (red) and rectum (yellow).  190 
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Figure 5.  Planned (solid lines) and estimated delivered dose volume histograms (dashed lines) based 
on the KIM-measured motion trace with KIM for fraction 1 of patient 1.   
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Future directions for the clinical implementation of the KIM method include extending to more 
prostate patients, SBRT, other cancer sites in the thorax, abdomen and pelvis, rotation, and potentially 
deformation. Additionally, imaging dose reduction methods could be explored as well as the 
integration with a respiratory monitor for cancer sites affected by periodic motion.  
This clinical implementation of KIM was performed on a Trilogy linear accelerator. As the 200 
KIM method requires only a gantry-mounted x-ray imager, the method could be applied on other linac 
models from the same vendor or linacs from other vendors provided the terms of the KIM technology 
(US Patent 8,379,794) Stanford University license are adhered to.  
Currently, the response to above tolerance motion by KIM is manual gating. Obvious next 
steps to improve safety and efficiently are to make this gating process automated and/or to link KIM 205 
to automatic MLC or couch adaptation.  
 
CONCLUSION 
After eight years of research and development, for the first time KIM has been clinically implemented 
for prostate cancer radiotherapy. The measured accuracy and precision were both sub-millimeter for 210 
the first treatment fraction. KIM is a real-time image guidance method using widely available 
radiotherapy technology. This clinical translational research milestone paves the way for the broad 
implementation of real-time tumor position monitoring with the detection and correction of geometric 
and dosimetric errors and resultant clinical outcomes in cancer radiotherapy. 
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